Direct Oral Anticoagulants in Patients With ESRD and Kidney Transplantation
Direct oral anticoagulant (DOAC) use has significantly increased because major medical organizations endorse their role for conditions in which anticoagulation is indicated. Owing to important pharmacokinetic properties, the use of apixaban and rivaroxaban requires careful consideration in at-risk p...
Saved in:
| Main Authors: | Nicholas W. Lange, Justin Muir, David M. Salerno |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Kidney International Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S246802492401982X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Meta-analysis comparing apixaban versus warfarin anticoagulation therapies for patients with severe renal insufficiency
by: LIANG Qiao-jing, et al.
Published: (2019-01-01) -
Use of direct oral anticoagulants in kidney diseases
by: I.A. Paliienko, et al.
Published: (2025-03-01) -
Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review
by: B. A. Tatarsky, et al.
Published: (2022-11-01) -
Hospital consumption of direct oral anticoagulants in regions of the Russian Federation in 2017–2022
by: A. V. Matveev, et al.
Published: (2024-01-01) -
Laboratory Predictors of Hemorrhagic Complications in Patients With Total Hip Arthroplasty and Treatment With Direct Oral Anticoagulants
by: L. B. Gaikovaya, et al.
Published: (2023-11-01)